Browse ROS1

Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein
Domain PF00041 Fibronectin type III domain
PF07714 Protein tyrosine kinase
Function

Orphan receptor tyrosine kinase (RTK) that plays a role in epithelial cell differentiation and regionalization of the proximal epididymal epithelium. May activate several downstream signaling pathways related to cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signaling pathway. Mediates the phosphorylation of PTPN11, an activator of this pathway. May also phosphorylate and activate the transcription factor STAT3 to control anchorage-independent cell growth. Mediates the phosphorylation and the activation of VAV3, a guanine nucleotide exchange factor regulating cell morphology. May activate other downstream signaling proteins including AKT1, MAPK1, MAPK3, IRS1 and PLCG2.

> Gene Ontology
 
Biological Process GO:0002064 epithelial cell development
GO:0002065 columnar/cuboidal epithelial cell differentiation
GO:0002066 columnar/cuboidal epithelial cell development
GO:0006817 phosphate ion transport
GO:0006820 anion transport
GO:0007283 spermatogenesis
GO:0010966 regulation of phosphate transport
GO:0015698 inorganic anion transport
GO:0016049 cell growth
GO:0018108 peptidyl-tyrosine phosphorylation
GO:0018212 peptidyl-tyrosine modification
GO:0031929 TOR signaling
GO:0032006 regulation of TOR signaling
GO:0038083 peptidyl-tyrosine autophosphorylation
GO:0044070 regulation of anion transport
GO:0046777 protein autophosphorylation
GO:0048232 male gamete generation
GO:0070371 ERK1 and ERK2 cascade
GO:0070372 regulation of ERK1 and ERK2 cascade
Molecular Function GO:0004713 protein tyrosine kinase activity
GO:0004714 transmembrane receptor protein tyrosine kinase activity
GO:0019199 transmembrane receptor protein kinase activity
GO:0019902 phosphatase binding
GO:0019903 protein phosphatase binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between ROS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between ROS1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
23072905LeukemiaInhibit immunity (NK cell function)Malignant granulocytes from patients with BCR-ABL-positive CML expressed the oxygen radical-producing enzyme NOX, produced large amounts of ROS, and triggered extensive cell death in NK cells.
29672044Colorectal CarcinomaInhibit immunityAndrographolide Antagonizes TNF-α-Induced IL-8 via Inhibition of NADPH Oxidase/ROS/NF-κB and Src/MAPKs/AP-1 Axis in Human Colorectal Cancer HCT116 Cells.
29669207melanomaInhibit immunityThe outcomes revealed that ROS-inducing ZnPP PM demonstrated specificity for the in vitro and in vivo targeting of macrophages, elevated the level of ROS, and lowered STAT3 expression in BM-TAMs.
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of ROS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of ROS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4730.0752
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.8570.157
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1980.66
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.5140.537
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.140.93
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3530.418
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.0740.93
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.0280.985
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.0560.974
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.9960.228
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 282.2110.0356
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-1.1350.00903
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of ROS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.812.32.50.744
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.813.61.21
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211728.629.4-0.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.5037.50.209
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131123.145.5-22.40.39
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.1011.10.36
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382718.411.17.30.503
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221318.215.42.81
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.87.111.70.602
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ROS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ROS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ROS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ROS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of ROS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between ROS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolROS1
NameROS proto-oncogene 1 , receptor tyrosine kinase
Aliases MCF3; ROS; c-ros-1; v-ros avian UR2 sarcoma virus oncogene homolog 1; v-ros UR2 sarcoma virus oncogene homol ......
Chromosomal Location6q21-q22
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting ROS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.